Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 2, 2026

Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *

View original at globenewswire.com
Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes * MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Autism Impact ETF (Ticker: ASD), the first exchange-traded fund designed to provide targeted exposure to publicly traded comp…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The ASD ETF is the first U.S.-listed ETF combining an autism-focused thematic index and a binding adviser-level commitment to donate net advisory profits to autism-related causes.

    60% confidence
  • Defiance ETFs was founded in 2018 and is a leading thematic and income-focused ETF issuer managing more than 75 ETFs and over $13.4 billion in assets under management.

    60% confidence
  • Defiance plans to donate 100% of the ETF's net profits in its first two years to autism-focused nonprofit organizations and a minimum of 50% of annual net profits thereafter.

    60% confidence
  • There are currently no FDA-approved medications addressing the core symptoms of autism spectrum disorder.

    60% confidence
  • Products based on the VettaFi Autism Impact Index are not sponsored, endorsed, sold, or promoted by VettaFi, and VettaFi makes no representation regarding the advisability of trading in such products.

    60% confidence
  • As parents of a profoundly autistic child, this launch is deeply personal to our family. Families impacted by autism face challenges every single day, and after experiencing that firsthand, we became committed to helping drive greater awareness, innovation, research, and support for the autism community.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com